Premium
Cell‐synthesized extracellular matrix particles for tissue engineering and aesthetic applications (87.2)
Author(s) -
L'Heureux Nicolas,
Young D,
Dusserre Nathalie,
Sonnenberg Sonya,
Johnson Todd,
McAllister Todd,
Rodriguez Ricardo,
Christman Karen
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.87.2
Subject(s) - extracellular matrix , adipose tissue , tissue engineering , adipogenesis , biomedical engineering , chemistry , regenerative medicine , microbiology and biotechnology , cell , medicine , biology , biochemistry
With age, or after injury, subcutaneous adipose and conjunctive tissue loss can cause poor aesthetic appearance. Current injectable tissue fillers trigger foreign body responses that eventually lead to their degradation or encapsulation. The ideal dermal filler would provide initial structural support but also trigger a regenerative process and lead to the creation of a new permanent tissue. The goal of this project is to develop a new class of fillers that provides long‐term results by triggering the regeneration of a stable, living and vascularized adipose tissue. Using the Tissue Engineering by Self‐Assembly (TESA) approach, sheets of ECM produced by normal human fibroblasts in vitro were dehydrated and reduced to a particulate form that could be injected subcutaneously in nude mice. The ECM particles caused minimal inflammation or encapsulations. Most notably, vascularization and adipogenesis were observed at the injection site, neither of which was noted when using two popular dermal fillers (Juvederm® or Radiesse®). Progression of adipogenesis around the ECM particles was noted throughout the duration of the study (3 months). In separate studies, particles were cast in vitro to produce finely channelized structures that could be seeded with endothelial cells. This approach offers a viable strategy for the production pre‐vascularized bulk tissue to address secretory organ tissue engineering. Conclusion: Fibroblast‐synthesized particles combine “off‐the‐shelf” availability and a persistent ECM that provides mechanical support while triggering the development of a vascularized adipose tissue. Clinical studies are underway to compare this new regenerative dermal filler with the standard of care.